MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
33.03
-2.53
-7.11%
After Hours: 33.20 +0.17 +0.51% 16:51 09/28 EDT
OPEN
35.00
PREV CLOSE
35.56
HIGH
35.19
LOW
32.91
VOLUME
8.52M
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
25.04
MARKET CAP
3.85B
P/E (TTM)
-7.0846
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Dow Jones · 1h ago
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver
Seeking Alpha · 5h ago
Weekly Report: what happened at VKTX last week (0921-0925)?
Weekly Report · 12h ago
Viking Therapeutics Rallies as Obesity Drug Hopes Rise
TipRanks · 2d ago
Benzinga Bulls and Bears: Costco, KB Home, McDonald’s
Benzinga · 2d ago
MarketBeat Week in Review – 09/21 - 09/25
Barchart · 2d ago
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 4.2%, Underperforms Peers
Dow Jones · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Lyell Immunopharma (LYEL)
TipRanks · 3d ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.